Efficacy and Safety of Fluoxetine in the Treatment of Patients With Major Depression After First Myocardial Infarction: Findings From a Double-Blind, Placebo-Controlled Trial
Jacqueline J. M. H. Strik, MD,
Adriaan Honig, MD, PhD, MRCPsych,
Richel Lousberg, PhD,
Aimée H. P. Lousberg,
Emile C. Cheriex, MD, PhD,
Hanneke G. Tuynman-Qua, MD, MFPM,
Petra M. J. C. Kuijpers, MD,
H. J. J. Wellens, MD, PhD and
H. M. Van Praag, MD, PhD
From the Departments of Psychiatry (J.J.M.H.S., A.H., A.H.P.L., P.M.J.C.K., H.M.V.P.) and Cardiology (E.C.C., P.M.J.C.K., M.F.P.M.H.J.J.W.), University Hospital Maastricht; Department of Psychiatry (J.J.M.H.S., A.H., R.L.), University of Maastricht; and Eli Lilly Netherlands (H.G.T.-Q.), Nieuwegein, The Netherlands.

View larger version (55K):
[in a new window]
|
Fig. 1. Flow chart of depressed patients eligible for the study.
|
|

View larger version (16K):
[in a new window]
|
Fig. 2. Efficacy of fluoxetine vs. placebo in depression in post-MI depression. w = week.
|
|

View larger version (14K):
[in a new window]
|
Fig. 3. Efficacy of fluoxetine vs. placebo in hostility in post-MI depression. w = week. p = .05.
|
|
Copyright © 2000 by the American Psychosomatic Society